History
| 1872 | Tokubei Torii established a company named Uenoya, at Sakai-Machi, Yokohama, for import of pharmaceuticals from the West. |
|---|---|
| 1909 |
Establishment of Uenoya's research laboratories, and start of dealing in Japanese pharmacopoeial drugs under the Torii brand name. |
| 1921(Nov.) |
Uenoya reorganized as Torii Shoten K.K. |
| 1949(May) | Company name changed to Torii Pharmaceutical Co., Ltd. |
| 1963(Apr.) | Torii introduced ALLERGEN (allergenic extracts) an agent developed in-house for allergy diagnosis and immunotherapy. |
| 1963(June) | Torii went public with over-the-counter stock transactions at the Tokyo Securities Dealers Association. |
| 1977(Oct.) | A new plant constructed at Sakura, Chiba Prefecture, in accordance with GMP (Good Manufacturing Practices ) standards. |
| 1990(Apr.) | Current Head Office building completed. |
| 1993(Oct.) | Torii's stock listed on the second section of the Tokyo Stock Exchange. |
| 1993(Nov.) |
Torii launched ANTEBATE ointment and cream (betamethasone butyrate propionate), a topical adrenocortical hormone. |
| 1995(Sept.) | Torii's stock listed on the first section of the Tokyo Stock Exchange. |
| 1998(Dec.) | Japan Tobacco Inc.(JT) purchased more than 50% of Torii's stock. |
| 1999(Oct.) | JT and Torii established a collaboration arrangement (Torii concentrates on marketing and JT, on R&D.) |
| 2009(Mar.) |
Torii launched the oral antipruritis drug REMITCH CAPSULES (nalfurafine hydrochloride), for which Toray Industries, Inc. obtained manufacturing and marketing approval. |
| 2014(May) |
Torii launched Riona Tablets (Ferric Citrate Hydrate) for the treatment of hyperphosphatemia, for which JT obtained manufacturing and marketing approval. |
| 2014(Oct.) |
Torii launched “CEDARTOLEN SUBLINGUAL DROP - Japanese Cedar Pollen” a Sublingual Immunotherapy Drug for Japanese Cedar Pollinosis. |
| 2015(Dec.) |
Torii launched “MITICURE House Dust Mite Sublingual Tablets” an Allergen Immunotherapy Tablet for House Dust Mite Allergy |
| 2018(June) |
Torii Launched “CEDARCURE ® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis. |
| 2020(June) |
Torii launched the CORECTIM (delgocitinib) ,Topical Janus kinase (JAK) inhibitor,for which JT obtained manufacturing and marketing approval. |
| 2020(July) | Torii transferred Sakura Plant to IWAKI SEIYAKU CO.,LTD.. |
| 2020(Dec.) |
Torii launched ENAROY Tablets (enarodustat) for the treatment of Anemia Associated with Chronic Kidney Disease, for which JT obtained manufacturing and marketing approval. |
| 2021(Apr.) |
Torii launched ORLADEYO Capsules, a plasma kallikrein inhibitor indicated for the suppression of the attacks in hereditary angioedema (HAE) ,for which OrphanPacific, Inc. obtained manufacturing and marketing approval. |